GO:0019043 establishment of viral latency: Molecular Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0019043 (establishment of viral latency) describes the process by which a virus enters a dormant state in its host, either as an integrated provirus or as an episome, with the viral genome persisting as a distinct object in the cytoplasm or nucleus.
• Herpesviruses such as Epstein-Barr virus (EBV), human cytomegalovirus (HCMV), and Kaposi's sarcoma-associated herpesvirus (KSHV) establish latency through coordinated expression of latency-associated proteins and non-coding RNAs that silence lytic genes.
• HIV-1 establishes latency primarily in resting CD4+ T cells and macrophages, where the provirus integrates into the host genome and becomes transcriptionally silent, creating a persistent reservoir that is the major barrier to cure.
• Epigenetic regulation, including DNA methylation, histone modifications, and chromatin remodeling, is central to the establishment and maintenance of viral latency.
• Viral entry pathways and host immune factors such as NLRC3 can shape the efficiency of latency establishment, as shown for HCMV and gammaherpesviruses.
• CRISPR-based knockout, knock-in, and overexpression models enable causal dissection of host and viral genes that control latency establishment, accelerating the development of latency-reversing or latency-promoting therapies.
Description
Viral latency is a survival strategy used by diverse viruses, including herpesviruses and retroviruses, to persist in the host for life. The Gene Ontology term GO:0019043, establishment of viral latency, captures the initial steps by which a virus transitions from an active replicative state to a dormant state, either by integrating its genome into the host chromosome as a provirus or by maintaining it as an episome in the nucleus or cytoplasm. This process is fundamental to viral pathogenesis because latent reservoirs evade immune clearance and antiviral therapy, and they can reactivate to cause recurrent disease. Understanding how latency is established is therefore critical for developing curative strategies against chronic viral infections such as HIV-1 and herpesvirus-associated malignancies. Research on GO:0019043 spans virology, immunology, and epigenetics. Studies have identified key viral proteins, such as EBV EBNA1 and HIV-1 Nef, that modulate the establishment of latency. Host factors, including chromatin-modifying enzymes and immune sensors like NLRC3, also play decisive roles in whether a virus commits to latency or lytic replication. The interplay between viral entry routes and host cell state further influences latency outcomes, as demonstrated for HCMV. These findings underscore the complexity of latency establishment and the need for robust experimental models to dissect the underlying mechanisms. For researchers, GO:0019043 provides a standardized framework to annotate genes and pathways involved in the early events of viral dormancy. By leveraging CRISPR gene editing and high-throughput screening, it is now possible to systematically identify host dependency factors and viral determinants that govern latency establishment, opening new avenues for therapeutic intervention.
establishment of viral latency At A Glance
| GO ID | GO:0019043 |
|---|---|
| GO term | establishment of viral latency |
| Ontology | biological_process |
| Synonym | lysogenic commitment, phage lysogeny |
| Definition | A process by which a virus establishes a latent state within its host, either as an integrated provirus within the host genome or as an episome, where the viral genome remains in the cytoplasm or nucleus as distinct objects. |
| Major function | Enables viruses to persist long-term in host cells by silencing lytic genes and maintaining the viral genome as a provirus or episome. |
| Related processes | Viral latency maintenance, reactivation from latency, epigenetic silencing, immune evasion. |
| Key viruses | Herpesviruses (EBV, HCMV, KSHV, HSV-1), retroviruses (HIV-1), bacteriophages (lambda). |
| Research relevance | Target for curative therapies against HIV-1 and herpesvirus-associated diseases; model for host-pathogen interactions and epigenetic regulation. |
What Is GO:0019043?
According to the Gene Ontology, GO:0019043 (establishment of viral latency) is defined as a process by which a virus establishes a latent state within its host, either as an integrated provirus within the host genome or as an episome, where the viral genome remains in the cytoplasm or nucleus as distinct objects. This term encompasses the initial commitment to latency, including the molecular events that silence lytic gene expression and allow the viral genome to persist without producing infectious progeny.
Why Is establishment of viral latency Important in Cell Biology?
GO:0019043 is critically important because latent viral reservoirs are the main obstacle to curing chronic viral infections such as HIV-1 and herpesvirus-associated malignancies. Latency allows viruses to evade immune responses and antiretroviral drugs, and reactivation can lead to severe disease. Understanding the establishment of latency at the molecular level provides targets for latency-reversing agents or latency-promoting strategies, and it illuminates fundamental mechanisms of gene regulation and epigenetic control.
• Latent HIV-1 reservoirs persist despite antiretroviral therapy and are the primary barrier to an HIV cure.
• Herpesviruses like EBV and KSHV establish lifelong latency linked to cancers such as Burkitt lymphoma and Kaposi sarcoma.
• HCMV latency is a major cause of congenital disabilities and complications in transplant patients.
• Epigenetic silencing during latency involves DNA methylation, histone deacetylation, and chromatin remodeling, offering druggable targets.
• Host immune sensors such as NLRC3 modulate latency establishment in B lymphocytes, linking innate immunity to viral dormancy.
• Viral proteins like Nef differentially govern latency establishment in lentiviruses, revealing species-specific mechanisms.
• CRISPR screens can identify host genes essential for latency establishment, accelerating therapeutic target discovery.
• Understanding latency establishment informs vaccine design and gene therapy vector safety.
• Latency models are valuable for studying viral oncogenesis and immune evasion.
• GO:0019043 provides a standardized annotation for comparative genomics of latent viruses.
What Happens During establishment of viral latency?
Viral Entry and Initial Host Cell Interactions
In simple terms: The virus first attaches to and enters a host cell, and the route of entry can influence whether it later becomes latent.
The establishment of viral latency begins with viral entry into a susceptible host cell. For HCMV, the entry pathway shapes the subsequent decision between lytic replication and latency, with different entry routes leading to distinct intracellular signaling and gene expression programs. Similarly, HIV-1 entry into CD4+ T cells and macrophages is a prerequisite for proviral integration and latency establishment. The initial interactions between viral envelope proteins and host receptors, as well as the activation state of the target cell, set the stage for latency commitment.
Genome Persistence: Integration or Episome Formation
In simple terms: The viral genome either inserts itself into the host DNA or remains as a separate circular piece, allowing it to stay in the cell for a long time.
A central step in latency establishment is the persistence of the viral genome. Retroviruses such as HIV-1 integrate their reverse-transcribed DNA into the host genome, forming a provirus that is replicated along with cellular DNA. Herpesviruses, including EBV and KSHV, typically maintain their genomes as multicopy episomes tethered to host chromosomes via viral proteins such as EBNA1 and LANA. In both cases, the viral genome remains as a distinct object in the nucleus, and this physical state is essential for the establishment of latency.
Silencing of Lytic Genes and Epigenetic Reprogramming
In simple terms: The virus turns off the genes it needs for active replication and wraps its DNA in chemical marks that keep those genes quiet.
Once the viral genome persists, the virus must silence lytic genes to avoid immune detection and cell death. This involves epigenetic modifications such as histone deacetylation, H3K9 methylation, and DNA methylation, which compact viral chromatin and repress lytic promoters. EBV latency establishment requires the coordinated expression of latency-associated proteins (e.g., EBNA1, EBNA2, EBNA3s, LMP1) that reprogram host gene expression and enforce viral gene silencing. In HIV-1, transcriptional interference and the absence of NF-kB and Tat activity contribute to proviral silencing. Host factors like NLRC3 can modulate these epigenetic events during gammaherpesvirus latency in B cells.
Expression of Latency-Associated Genes and Non-Coding RNAs
In simple terms: Even while quiet, the virus produces a small set of products that help it stay hidden and keep the host cell alive.
Latency is not completely silent; viruses express a limited repertoire of latency-associated genes and non-coding RNAs that maintain the latent state and promote host cell survival. EBV expresses EBERs, BARTs, and EBNA1, which contribute to immune evasion and episome maintenance. KSHV expresses LANA and viral microRNAs that regulate host and viral gene expression. HIV-1 latency is associated with the expression of viral proteins such as Nef in some models, which can influence the establishment of latency in a species-specific manner. These latency-associated factors are critical for the long-term persistence of the virus.
Host Cell Reprogramming and Immune Evasion
In simple terms: The virus changes how the host cell behaves and hides from the immune system so it can survive undetected.
Establishment of viral latency involves active reprogramming of host cell biology to create a favorable niche. Herpesviruses modulate cell cycle, apoptosis, and immune signaling pathways to prevent cell death and immune recognition. For example, EBV latency proteins downregulate antigen presentation and inhibit apoptosis, while HCMV latency alters the expression of cellular genes involved in immune surveillance. In HIV-1, latently infected cells evade immune clearance partly because viral antigens are not expressed on the cell surface. Host innate immune sensors such as NLRC3 can either promote or restrict latency establishment, highlighting the complex interplay between virus and host immunity.
Key Genes Involved in GO:0019043 establishment of viral latency
The following genes and proteins are central to the establishment of viral latency, as documented in the literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| EBNA1 (EBV) | Maintains episomal viral genome and tethers it to host chromosomes | Essential for EBV latency establishment; target for anti-EBV therapies |
| EBNA2 (EBV) | Transactivates viral and cellular genes to drive B-cell transformation | Key regulator of EBV latency III program |
| LMP1 (EBV) | Mimics CD40 signaling to promote B-cell survival and proliferation | Oncogenic driver in EBV-associated lymphomas |
| LANA (KSHV) | Tethers KSHV episome to host chromatin and regulates viral gene expression | Critical for KSHV latency and associated malignancies |
| Nef (HIV-1/SIV) | Modulates host cell signaling and immune evasion; influences latency establishment | Differentially governs latency in lentiviruses |
| Tat (HIV-1) | Transactivates viral transcription; its absence favors latency | Central to HIV-1 latency reversal strategies |
| NF-kB | Host transcription factor that activates HIV-1 LTR; its absence promotes latency | Target for latency-reversing agents |
| CTIP2 (BCL11B) | Recruits chromatin-modifying enzymes to silence HIV-1 LTR | Host restriction factor for HIV-1 latency |
| HDAC1/2 | Deacetylate histones to repress viral promoters | Enzymes maintaining latent viral chromatin |
| DNMT1/3A/3B | DNA methyltransferases that methylate viral promoters | Epigenetic silencing of latent viral genomes |
| NLRC3 | Host innate immune sensor that bidirectionally regulates gammaherpesvirus latency | Modulates latency establishment in B lymphocytes |
| IE1/IE2 (HCMV) | Immediate-early proteins that are silenced during latency | Their repression is a hallmark of HCMV latency |
| UL138 (HCMV) | Latency-associated protein that promotes viral genome maintenance | Required for HCMV latency establishment |
| EBERs (EBV) | Non-coding RNAs that modulate immune responses | Abundant in EBV latency; potential biomarkers |
| BARTs (EBV) | Non-coding RNAs and microRNAs that regulate latency | Modulate host and viral gene expression |
| Vpr (HIV-1) | Accessory protein that influences cell cycle and latency | Modulates establishment of HIV-1 latency |
| SIRT1 | Deacetylase that regulates HIV-1 latency | Host factor affecting proviral silencing |
| SP1 | Host transcription factor that binds HIV-1 LTR | Involved in basal and Tat-mediated transcription |
How Is establishment of viral latency Regulated?
The establishment of viral latency is tightly regulated by both viral and host factors. Epigenetic mechanisms, including histone deacetylation by HDACs, histone methylation, and DNA methylation by DNMTs, repress viral lytic promoters and maintain the latent state. Host transcription factors such as NF-kB and SP1 can activate the HIV-1 LTR, and their absence or inhibition promotes latency. Viral proteins like EBNA2 and LANA orchestrate the expression of latency-associated genes and modulate host signaling pathways. Innate immune sensors such as NLRC3 can bidirectionally regulate gammaherpesvirus latency in B cells, indicating that host immunity actively shapes latency outcomes. Additionally, the route of viral entry and the activation state of the host cell can influence the establishment of latency, as shown for HCMV.
establishment of viral latency and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HIV-1 provirus | AIDS, latent reservoir | Primary CD4+ T cell latency model; CRISPR KO of host dependency factors |
| EBNA1 (EBV) | Burkitt lymphoma, nasopharyngeal carcinoma | EBV-infected B cell lines; CRISPR KO or knock-in of EBNA1 |
| LANA (KSHV) | Kaposi sarcoma, primary effusion lymphoma | KSHV-infected endothelial or B cell lines; CRISPR KO of LANA |
| UL138 (HCMV) | Congenital HCMV, transplant complications | CD34+ hematopoietic progenitor cell latency model; CRISPR KO of UL138 |
| NLRC3 | Gammaherpesvirus latency and lymphoproliferation | MHV-68 infection of B cells; CRISPR KO or overexpression of NLRC3 |
HIV-1 Latency and AIDS
HIV-1 establishes latent proviral reservoirs in resting CD4+ T cells and macrophages, which persist despite antiretroviral therapy and are the major barrier to a cure. The establishment of latency allows the virus to evade immune responses and rebound upon treatment interruption. Understanding the molecular mechanisms of latency establishment is essential for developing strategies to eliminate the reservoir, such as shock-and-kill or block-and-lock approaches.
Herpesvirus-Associated Malignancies
EBV and KSHV establish lifelong latency that is associated with several cancers, including Burkitt lymphoma, Hodgkin lymphoma, nasopharyngeal carcinoma, and Kaposi sarcoma. Latency-associated viral proteins and non-coding RNAs drive oncogenesis by promoting cell proliferation, survival, and immune evasion. Targeting the establishment of latency or the latent state itself is a promising therapeutic strategy for these malignancies.
Congenital HCMV Infection and Transplant Complications
Human cytomegalovirus (HCMV) establishes latency in myeloid progenitor cells and can reactivate to cause severe disease in immunocompromised individuals, including transplant recipients and congenitally infected infants. The establishment of HCMV latency is influenced by the route of viral entry and host cell state, and understanding these mechanisms may lead to interventions that prevent reactivation.
Gammaherpesvirus Latency and Immune Regulation
Gammaherpesviruses such as murine gammaherpesvirus 68 (MHV-68) establish latency in B lymphocytes, and host factors like NLRC3 modulate this process. Dysregulation of latency can contribute to lymphoproliferative disorders. Studying the interplay between host immunity and latency establishment provides insights into viral pathogenesis and potential immunotherapies.
From establishment of viral latency-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does a host gene promote or restrict latency establishment? | CRISPR knockout in primary CD4+ T cells or B cell lines followed by HIV-1 or EBV infection |
| What is the role of a specific viral protein in latency? | CRISPR knockout or point mutation of the viral gene in an infectious clone |
| How does a disease-associated mutation affect latency? | Knock-in of the mutation in a cell line or primary cells, followed by latency assays |
| Where and when is a latency-associated protein expressed? | Tagged knock-in (e.g., GFP or HA) for imaging and immunoprecipitation |
| Can overexpression of a factor drive latency? | Overexpression of the gene of interest in a permissive cell line, followed by infection and latency quantification |
| What is the epigenetic landscape during latency? | CRISPR epigenome editing or knockout of epigenetic modifiers, combined with ChIP-seq |
How to Study the establishment of viral latency Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Host genes required for or restricting latency | Identify therapeutic targets in HIV-1 and herpesvirus latency |
| ChIP-seq | Histone modifications and protein binding on viral chromatin | Map repressive marks during latency establishment |
| Bisulfite sequencing | DNA methylation of viral promoters | Assess epigenetic silencing of latent genomes |
| RNA-seq | Viral and host transcriptomes | Characterize latency-associated gene expression |
| FISH | Localization of viral genomes in host cells | Visualize episome or provirus nuclear positioning |
| Single-cell RNA-seq | Heterogeneity of latency establishment | Identify cell-to-cell variability in latency outcomes |
| Proteomics | Protein expression and interactions during latency | Discover host factors binding viral latency proteins |
| Reporter virus assays | Latency establishment and reactivation efficiency | Screen for latency-modulating compounds or genes |
CRISPR Screens for Host Factors
Genome-wide CRISPR knockout or activation screens can identify host genes that are essential for or restrict the establishment of viral latency. For example, screens in HIV-1 latency models have uncovered factors involved in proviral silencing and reactivation. Similar approaches can be applied to herpesviruses to discover novel latency regulators.
Epigenomic Profiling
Chromatin immunoprecipitation followed by sequencing (ChIP-seq) and bisulfite sequencing can map histone modifications and DNA methylation on viral genomes during latency establishment. These methods have revealed that repressive marks such as H3K9me3 and H3K27me3 are enriched on latent viral promoters.
Transcriptomics and RNA-seq
RNA sequencing of latently infected cells can identify viral and host transcripts expressed during latency. This approach has been used to characterize latency-associated gene expression programs in EBV, KSHV, and HIV-1.
Imaging and Single-Cell Approaches
Fluorescence in situ hybridization (FISH) and live-cell imaging can visualize viral genomes and their nuclear localization during latency establishment. Single-cell RNA-seq can capture heterogeneity in latency outcomes among infected cells.
How CRISPR Can Be Used to Study GO:0019043 establishment of viral latency
Knockout
CRISPR knockout of host or viral genes is widely used to test their necessity in the establishment of viral latency. For example, knocking out the HIV-1 provirus or host dependency factors can prevent or enhance latency establishment in cell models. In herpesviruses, knockout of latency-associated genes such as EBNA1 or LANA abolishes episome maintenance and latency.
Point Mutation
Introducing precise point mutations into viral or host genes allows researchers to dissect functional domains and post-translational modification sites involved in latency. For instance, point mutations in the HIV-1 LTR or in Nef can alter the efficiency of latency establishment. Similar approaches can be applied to herpesvirus latency proteins to map critical residues.
Knock-in
Knock-in of reporter tags (e.g., GFP, luciferase) or disease-associated alleles enables real-time monitoring of latency establishment and functional studies. Tagged knock-in of viral genes such as EBNA1 or LANA facilitates imaging and proteomic analysis of latency complexes. Knock-in of host mutations can model genetic susceptibility to latency.
Overexpression
Overexpression of host or viral genes can drive or inhibit latency establishment. For example, overexpression of the HIV-1 Tat protein prevents latency by activating the LTR, while overexpression of CTIP2 promotes silencing. Overexpression of NLRC3 modulates gammaherpesvirus latency in B cells. These models are useful for gain-of-function studies.
How EDITGENE Supports establishment of viral latency Research
Researchers studying establishment of viral latency-related genes often need to determine whether a candidate gene is causally involved in the process or merely correlated with it. EDITGENE provides a comprehensive suite of CRISPR-based services to enable precise genetic manipulation and functional interrogation of latency-associated genes in relevant cell models.
Contact EDITGENE today to design your custom CRISPR model for establishment of viral latency research.
Frequently Asked Questions About establishment of viral latency
What is establishment of viral latency (GO:0019043)?
It is the biological process by which a virus enters a dormant state in a host cell, either by integrating its genome as a provirus or maintaining it as an episome, and silencing lytic genes.
What genes are involved in the establishment of viral latency?
Key genes include EBV EBNA1, EBNA2, LMP1; KSHV LANA; HIV-1 Nef, Tat; host factors NF-kB, CTIP2, HDACs, DNMTs, and NLRC3.
How do herpesviruses establish latency?
Herpesviruses such as EBV and KSHV maintain their genomes as episomes, express latency-associated proteins and non-coding RNAs, and epigenetically silence lytic genes.
How does HIV-1 establish latency?
HIV-1 integrates its provirus into host DNA, primarily in resting CD4+ T cells, and becomes transcriptionally silent due to epigenetic repression and lack of NF-kB/Tat activity.
What is the role of epigenetics in viral latency?
Epigenetic modifications such as histone deacetylation, H3K9 methylation, and DNA methylation repress viral lytic promoters and maintain the latent state.
Which viruses use lysogeny?
Bacteriophage lambda is the classic example of lysogeny, and the term is synonymous with establishment of viral latency.
Why is viral latency important for disease?
Latent reservoirs cause persistent infections, evade immune responses and drugs, and can reactivate to cause disease, as seen in HIV/AIDS and herpesvirus-associated cancers.
How can CRISPR be used to study viral latency?
CRISPR knockout, knock-in, and overexpression models allow functional testing of host and viral genes, while screens identify novel regulators of latency establishment.
What cell models are used to study latency establishment?
Common models include primary CD4+ T cells for HIV-1, EBV-infected B cell lines, KSHV-infected endothelial cells, and CD34+ progenitor cells for HCMV.
What are latency-reversing agents?
These are compounds or genetic interventions that reactivate latent virus, making it visible to the immune system or susceptible to antiviral drugs; they are a key strategy for HIV cure.
Conclusion
The establishment of viral latency (GO:0019043) is a fundamental process that enables viruses to persist lifelong in their hosts, posing major challenges for the treatment of HIV-1 and herpesvirus infections. Research has elucidated key viral and host factors, epigenetic mechanisms, and entry-dependent signals that govern latency commitment. Continued investigation using advanced CRISPR models and high-throughput screens will uncover new therapeutic targets and bring us closer to curative strategies. EDITGENE is dedicated to supporting this research with state-of-the-art gene editing services, from knockout and knock-in cell models to CRISPR library screening and bioinformatics, empowering scientists to dissect the molecular basis of viral latency.
References
- 1. Murata T et al.. 2021. Molecular Basis of Epstein-Barr Virus Latency Establishment and Lytic Reactivation.. Viruses 13(12) PMID: 34960613
- 2. Bouchat S et al.. 2019. [Viral latency of HIV-1].. Virologie (Montrouge) 23(4):195-210 PMID: 31414658
- 3. Kitsberg Y et al.. 2025. Viral entry shapes HCMV latency establishment.. Nat Commun 17(1):1300 PMID: 41457095
- 4. Carlin E et al.. 2022. Lentiviral Nef Proteins Differentially Govern the Establishment of Viral Latency.. J Virol 96(7):e0220621 PMID: 35266804
- 5. Cohen JI. 2020. Herpesvirus latency.. J Clin Invest 130(7):3361-3369 PMID: 32364538
- 6. Lieberman PM. 2016. Epigenetics and Genetics of Viral Latency.. Cell Host Microbe 19(5):619-28 PMID: 27173930
- 7. Alum EU et al.. 2024. Toward a cure - Advancing HIV/AIDs treatment modalities beyond antiretroviral therapy: A Review.. Medicine (Baltimore) 103(27):e38768 PMID: 38968496
- 8. Kang HR et al.. 2024. Dynamic bidirectional regulation of NLRC3 and gammaherpesviruses during viral latency in B lymphocytes.. J Med Virol 96(3):e29504 PMID: 38445794
